Actavis to acquire Alpharma's Human Generics business
Actavis becomes one of top 5 global generics players
Actavis Group announced that it has agreed to acquire the human generics business of the US listed pharmaceutical company, Alpharma Inc., for a total consideration of US$810 million in cash. The deal brings together two premier generic pharmaceutical businesses with complementary strengths in Europe and the US and represents a significant milestone in Actavis' goal to become one of the leading global companies within the sector.
The combination of Actavis' brand and geographic coverage in Europe and the US with Alpharma's attractive position in the US market and own label sales in key European markets is expected to generate substantial opportunities to drive revenue growth, provide significant synergies and create shareholder value for the enlarged Group. Following the acquisition Actavis will be among the five largest companies in generic pharmaceuticals worldwide, in terms of revenue.
The enlarged Group will have one of the broadest portfolios in the generics sector with over 600 products on the market. Alpharma's strong liquid product portfolio complements Actavis' strengths in oral solid-dose products and there is minimal overlap in both pipeline and portfolios for the US market.
Other news from the department business & finance
